Jana Petrkova

Jana Petrkova

Auto-generated profile, based on publicly available information

Jana Petrkova

Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in Clinica Chimica Acta
Verified
Journal Article
Closed access
ITIrina P. Tereshchenko
Irina P. Tereshchenko
JPJana Petrkova
Jana Petrkova
FMFrantisek Mrazek
Frantisek Mrazek
JLJan Lukl
Jan Lukl
VMVladimir N. Maksimov
Vladimir N. Maksimov
MPMartin Petrek
Martin Petrek

1 January 2011 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
ITIrina P. Tereshchenko
Irina P. Tereshchenko
JPJana Petrkova
Jana Petrkova
MVMikhail I. Voevoda
Mikhail I. Voevoda
MTMilos Taborsky
Milos Taborsky
ZNZdenka Navratilova
Zdenka Navratilova
MPMartin Petrek
Martin Petrek
Coronary artery inflammation is a critical process in the pathogenesis of myocardial infarction (MI). The chemokine CCL5/RANTES (regulated upon activation, normal T cells expressed and secreted) is expressed in advanced atherosclerotic lesions. Functional polymorphisms of the RANTES gene can, therefore, be involved in the pathogenesis of coronary artery disease. We examined the association of polymorphisms in the RANTES gene with myocardial infarction in Slavonic populations of Czech and Russian origin. A total of 467 post-MI patients and 337 control subjects were genotyped for RANTES promoter G-403A (rs2107538) and intron 1.1 T/C (rs2280789) variants by PCR-SSP. Both RANTES genotypes and allele frequencies did not differ between case and control groups. Haplotype-based analysis also failed to reveal an association between MI and investigated markers. Strong linkage disequilibrium was detected between particular RANTES alleles. The data do not support an association between RANTES G-403A polymorphism and MI, as reported previously.

26 June 2019 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
JPJana Petrkova
Jana Petrkova
JBJana Borucka
Jana Borucka
MKMartin Kalab
Martin Kalab
PKPetra Klevcova
Petra Klevcova
JMJaroslav Michalek
Jaroslav Michalek
MPMartin Petrek
Martin Petrek
MiR-146a has been implicated in the regulation of the immune response as well as in inflammatory process of atherosclerosis. In the present study, we have investigated the expression of miR-146a and its targets, TLR4 a IRAK1, in aortic valve stenosis. A total of 58 patients with aortic stenosis (non- and atherosclerotic; tissue obtained during standard aortic valve replacement) were enrolled. The relative expression of mir-146a was higher in valvular tissue from patients with atherosclerosis compared to those without atherosclerosis (p = 0.01). Number of the IRAK1 and TLR4 transcripts did not differ between the investigated groups. There was a trend toward elevation of miR-146a expression in context of inflammatory infiltrate observed in the valvular tissue from patients with atherosclerosis (p = 0.06). In conclusion, in line with the acknowledged role of miR-146a in atherosclerotic inflammation, our data suggest it may be extended to the specific location of aortic valves in aortic stenosis.

5 July 2016 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
STStana Tokic
Stana Tokic
MŠMario Štefanić
Mario Štefanić
Ljubica Glavaš-ObrovacLjubica Glavaš-Obrovac
Ljubica Glavaš-Obrovac
SJSonja Jaman
Sonja Jaman
ENEva Novosadová
Eva Novosadová
MPMartin Petrek
Martin Petrek
Hashimoto’s thyroiditis (HT) is an organ-specific autoimmune disorder characterized by progressive thyroid failure. Th1 and Treg subset of CD4+ cells have been implicated in the pathogenesis; however, less is known about their respective roles across the spectrum of HT clinical presentations. To shed more light on CD4+ subsets role in HT, we investigated the mRNA expression levels of several Th1/Treg-associated transcription factors (T-bet/ETS1, HIF1α/BLIMP1/FOXP3) in peripheral blood T cells of 10 hypothyroid, untreated HT patients, 10 hypothyroid patients undergoing hormone replacement therapy, 12 euthyroid HT subjects, and 11 healthy controls by the qRT-PCR. Compared to euthyroid HT patients and controls, both hypothyroid (2.34-fold difference versus controls, P<0.01) and thyroxine-supplemented patients (2.5-fold, P<0.001) showed an increased FOXP3 mRNA expression in T cells. Similarly, mRNA expression levels of T-bet were upregulated in severely affected but not in euthyroid HT subjects (2.37-fold and 3.2-fold, hypothyroid and thyroxine-supplemented HT patients versus controls, resp., P<0.01). By contrast, no differences in mRNA expression levels of ETS1, BLIMP1, and HIF1α were observed across the study groups. In summary, severe but not euthyroid HT was associated with robust upregulation of T-bet and FOXP3 mRNA in peripheral T cells, independent of the thyroid hormone status but proportional to disease activity.

1 December 2016 in Archivum Immunologiae et Therapiae Experimentalis
Verified
Journal Article
Closed access
PDF file
MPMartin Petrek
Martin Petrek
LKLenka Kocourkova
Lenka Kocourkova
VZVeronika Zizkova
Veronika Zizkova
ZNZdenek Nosek
Zdenek Nosek
MTMilos Taborsky
Milos Taborsky
JPJana Petrkova
Jana Petrkova
Distribution of cytochrome P450 2C19 enzyme gene (CYP2C19) variants affecting metabolism of clopidogrel was determined in 526 Czech patients after percutaneous coronary intervention using MassARRAY genotyping and compared to distribution in other populations of European descent. Fifty-three (10%) patients underwent parallel determination of CYP2C19 genotypes from buccal swabs by a point of care technique with 100% concordance to the main genotyping platform. Observed CYP2C19 genotypes were related to clopidogrel metabolism phenotypes and discussed in population context. Hereby, presented methodologies provide accurate CYP2C19 genotyping results in a relatively short time of one up to 12 h and may, therefore, find the relevant place in the field of genotype-guided antiplatelet therapy.

17 October 2018
Verified
Book Chapter
Open access
PDF file
JPJana Petrkova
Jana Petrkova
MTMilos Taborsky
Milos Taborsky
MPMartin Petrek
Martin Petrek
Statins are very effective for lowering low-density lipoprotein cholesterol for primary and secondary cardiovascular disease prevention. While statins are usually well tolerated, individual response to statin therapy varies and intolerance, predominantly muscle symptoms, may appear in a significant proportion of patients. Besides clinical factors, variation in genes coding for proteins with drug transporting, immune or enzymatic function have been implicated in the pathogenesis of statin intolerance. In this review, we will characterise the candidate gene variants for development of statin intolerance, describe their population distribution and summarise current knowledge on their biological plausibility. Clinical relevance and current guidelines/recommendations will be also discussed.